Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.

Drach J, Huang H, Samoilova O, Belch A, Farber C, Bosly A, Novak J, Zaucha J, Dascalescu A, Bunworasate U, Masliak Z, Vilchevskaya K, Robak T, Pei L, Rooney B, van de Velde H, Cavalli F

Open source

DOI: 10.1080/10428194.2017.1365855
Published: 2018 Apr
Container: Leukemia & lymphoma
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/10428194.2017.1365855,
  title = {Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.},
  author = {Drach J and Huang H and Samoilova O and Belch A and Farber C and Bosly A and Novak J and Zaucha J and Dascalescu A and Bunworasate U and Masliak Z and Vilchevskaya K and Robak T and Pei L and Rooney B and van de Velde H and Cavalli F},
  year = {2018},
  journal = {Leukemia \& lymphoma},
  doi = {10.1080/10428194.2017.1365855},
  url = {https://doi.org/10.1080/10428194.2017.1365855}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.
AU  - Drach J
AU  - Huang H
AU  - Samoilova O
AU  - Belch A
AU  - Farber C
AU  - Bosly A
AU  - Novak J
AU  - Zaucha J
AU  - Dascalescu A
AU  - Bunworasate U
AU  - Masliak Z
AU  - Vilchevskaya K
AU  - Robak T
AU  - Pei L
AU  - Rooney B
AU  - van de Velde H
AU  - Cavalli F
PY  - 2018
JO  - Leukemia & lymphoma
DO  - 10.1080/10428194.2017.1365855
UR  - https://doi.org/10.1080/10428194.2017.1365855
ER  -

APA

J, D., H, H., O, S., A, B., C, F., A, B., J, N., J, Z., A, D., U, B., Z, M., K, V., T, R., L, P., B, R., H, V. D. V., & F, C. (2018). Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.. Leukemia & lymphoma. https://doi.org/10.1080/10428194.2017.1365855

Source records

pubmed · retrieved 2026-09-27T10:28:56.240Z
europe-pmc · retrieved 2026-09-27T10:28:56.246Z